Renae Judy

Renae Judy

Auto-generated profile, based on publicly available information

Renae Judy

Department of Surgery, University of Pennsylvania Perelman School of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
AVAnurag Verma
Anurag Verma
SDScott M. Damrauer
Scott M. Damrauer
NNNawar Naseer
Nawar Naseer
JWJoEllen Weaver
JoEllen Weaver
CKColleen M. Kripke
Colleen M. Kripke
FBFor The Penn Medicine BioBank
For The Penn Medicine BioBank
The Penn Medicine BioBank (PMBB) is an electronic health record (EHR)-linked biobank at the University of Pennsylvania (Penn Medicine). A large variety of health-related information, ranging from diagnosis codes to laboratory measurements, imaging data and lifestyle information, is integrated with genomic and biomarker data in the PMBB to facilitate discoveries and translational science. To date, 174,712 participants have been enrolled into the PMBB, including approximately 30% of participants of non-European ancestry, making it one of the most diverse medical biobanks. There is a median of seven years of longitudinal data in the EHR available on participants, who also consent to permission to recontact. Herein, we describe the operations and infrastructure of the PMBB, summarize the phenotypic architecture of the enrolled participants, and use body mass index (BMI) as a proof-of-concept quantitative phenotype for PheWAS, LabWAS, and GWAS. The major representation of African-American participants in the PMBB addresses the essential need to expand the diversity in genetic and translational research. There is a critical need for a “medical biobank consortium” to facilitate replication, increase power for rare phenotypes and variants, and promote harmonized collaboration to optimize the potential for biological discovery and precision medicine.

8 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MYMengyao Yu
Mengyao Yu
CTCatherine Tcheandjieu
Catherine Tcheandjieu
AGAdrien Georges
Adrien Georges
KXKe Xiao
Ke Xiao
HTHelio Tejeda
Helio Tejeda
JPJames R. Priest
James R. Priest
The fibrous annulus of the mitral valve plays an important role in valvular function and cardiac physiology, while normal variation in the size of cardiovascular anatomy may share a genetic link with common and rare disease. We derived automated estimates of mitral valve annular diameter in the 4-chamber view from 32,220 MRI images from the UK Biobank at ventricular systole and diastole as the basis for GWAS. Mitral annular dimensions corresponded to previously described anatomical norms, and GWAS inclusive of 4 population strata identified 10 loci, including possibly novel loci ( GOSR2 , ERBB4 , MCTP2 , MCPH1 ) and genes related to cardiac contractility ( BAG3 , TTN , RBFOX1 ). ATAC-Seq of primary mitral valve tissue localized multiple variants to regions of open chromatin in biologically relevant cell types and rs17608766 to an algorithmically predicted enhancer element in GOSR2 . We observed strong genetic correlation with measures of contractility and mitral valve disease and clinical correlations with heart failure, cerebrovascular disease, and ventricular arrhythmias. Polygenic scoring of mitral valve annular diameter in systole was predictive of risk mitral valve prolapse across 4 cohorts. In summary, genetic and clinical studies of mitral valve annular diameter revealed genetic determinants of mitral valve biology, while highlighting clinical associations. Polygenic determinants of mitral valve annular diameter may represent an independent risk factor for mitral prolapse. Overall, computationally estimated phenotypes derived at scale from medical imaging represent an important substrate for genetic discovery and clinical risk prediction.

1 June 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
LWLu-Chen Weng
Lu-Chen Weng
SKShaan Khurshid
Shaan Khurshid
AHAmelia Weber Hall
Amelia Weber Hall
VNVictor Nauffal
Victor Nauffal
VMValerie N. Morrill
Valerie N. Morrill
SLSteven A. Lubitz
Steven A. Lubitz
BACKGROUND: Substantial data support a heritable basis for supraventricular tachycardias, but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood. We sought to identify genetic loci associated with atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular accessory pathways or atrioventricular reciprocating tachycardia (AVAPs/AVRT). METHODS: We performed multiancestry meta-analyses of genome-wide association studies to identify genetic loci for AVNRT (4 studies) and AVAP/AVRT (7 studies). We assessed evidence supporting the potential causal effects of candidate genes by analyzing relations between associated variants and cardiac gene expression, performing transcriptome-wide analyses, and examining prior genome-wide association studies. RESULTS: Analyses comprised 2384 AVNRT cases and 106 489 referents, and 2811 AVAP/AVRT cases and 1,483 093 referents. We identified 2 significant loci for AVNRT, which implicate NKX2-5 and TTN as disease susceptibility genes. A transcriptome-wide association analysis supported an association between reduced predicted cardiac expression of NKX2-5 and AVNRT. We identified 3 significant loci for AVAP/AVRT, which implicate SCN5A , SCN10A , and TTN/CCDC141 . Variant associations at several loci have been previously reported for cardiac phenotypes, including atrial fibrillation, stroke, Brugada syndrome, and electrocardiographic intervals. CONCLUSIONS: Our findings highlight gene regions associated with ion channel function (AVAP/AVRT), as well as cardiac development and the sarcomere (AVAP/AVRT and AVNRT) as important potential effectors of supraventricular tachycardia susceptibility.

1 June 2025 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
SAShaunak S. Adkar
Shaunak S. Adkar
JLJulie A Lynch
Julie A Lynch
RCRyan B. Choi
Ryan B. Choi
TRTanmoy Roychowdhury
Tanmoy Roychowdhury
RJRenae L. Judy
Renae L. Judy
DKDerek Klarin
Derek Klarin
BACKGROUND: The genetic risk of intracranial aneurysm (IA) development has been ascribed to the genetic risk of smoking exposure and hypertension. The relationship of IA to other cardiovascular traits and the contribution of IA risk loci to aberrant gene programs within cerebrovascular cell types remains unclear. METHODS: We performed a genome-wide association study in the Million Veteran Program and Finnish cohort study testing association of roughly 25 million DNA variants with unruptured IA (4694 cases and 877 091 controls) in individuals of European, African, and Hispanic ancestries. Meta-analysis with publicly available summary statistics generated a final cohort of 15 438 cases and 1 183 973 controls. We constructed a cerebrovascular single-nuclear RNA sequencing data set and integrated IA summary statistics to prioritize candidate causal cell types. We constructed a polygenic risk score to identify patients at risk of developing IA. RESULTS: We identified 5 novel associations with IA, increasing the number of known susceptibility loci to 22. At these susceptibility loci, we prioritized 17 candidate causal genes. We found a significant positive genetic correlation of IA with coronary artery disease and abdominal aortic aneurysm. Integration of an IA gene set with cerebrovascular single-nuclear RNA sequencing data revealed a significant association with pericytes and smooth muscle cells. Finally, a polygenic risk score was significantly associated with IA across European (odds ratio, 1.87 [95% CI, 1.61–2.17]; P =8.8×10 − 17 ), African (odds ratio, 1.62 [95% CI, 1.19–2.15]; P =1.2×10 − 3 ), and Hispanic (odds ratio, 2.28 [95% CI, 1.47–3.38]; P =1.0×10 − 4 ) ancestries. CONCLUSIONS: Here, we identify 5 novel loci associated with IA. Integration of summary statistics with cerebrovascular single-nuclear RNA sequencing reveals an association of cell types involved in matrix production. We validated a polygenic risk score that predicts IA, controlling for demographic variables including smoking status and blood pressure. Our findings suggest that a deficit in matrix production may drive IA pathogenesis independent of hypertension and smoking.

1 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CTCatherine Tcheandjieu
Catherine Tcheandjieu
XKXiao Ke
Xiao Ke
HTHeliodoro Tejeda
Heliodoro Tejeda
JLJulie A Lynch
Julie A Lynch
SRSanni Ruotsalainen
Sanni Ruotsalainen
JPJames Priest
James Priest
Enlargement of the aorta is an important risk factor for aortic aneurysm and dissection, a leading cause of morbidity in the developed world. While Mendelian genetics account for a portion of thoracic aortic disease, the contribution of common variation is not known. Using standard techniques in computer vision, we performed automated extraction of Ascending Aortic Diameter (AsAoD) from cardiac MRI of 36,021 individuals from the UK Biobank. A multi-ethnic genome wide association study and trans-ethnic meta-analysis identified 99 lead variants across 71 loci including genes related to cardiovascular development (HAND2, TBX20) and Mendelian forms of thoracic aortic disease (ELN, FBN1). A polygenic risk score predicted prevalent risk of thoracic aortic aneurysm within the UK Biobank (OR 1.50 per standard deviation (SD) polygenic risk score (PRS), p=6.30x10-03) which was validated across three additional biobanks including FinnGen, the Penn Medicine Biobank, and the Million Veterans Program (MVP) in individuals of European descent (OR 1.37 [1.31 - 1.43] per SD PRS), individuals of Hispanic descent (OR 1.40 [1.16 - 1.69] per SD PRS, p=5.6x10-04), and individuals of African American descent (OR 1.08 [1.00 - 1.18] per SD PRS, p=0.05). Within individuals of European descent who carried a diagnosis of thoracic aneurysm, the PRS was specifically predictive of the need for surgical intervention (OR 1.57 [1.15 - 2.15] per SD PRS, p=4.45x10-03). Using Mendelian Randomization our data highlight the primary causal role of blood pressure in reducing dilation of the thoracic aorta. Overall our findings link normal anatomic variation to extremes observed in Mendelian syndromes and provide a roadmap for the use of genetic determinants of human anatomy in both understanding cardiovascular development while simultaneously improving prediction and prevention of human disease.

1 October 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
JDJohn DePaolo
John DePaolo
GBGina Biagetti
Gina Biagetti
RJRenae Judy
Renae Judy
GWGrace J. Wang
Grace J. Wang
JKJohn J. Kelly
John J. Kelly
SDScott M. Damrauer
Scott M. Damrauer
BACKGROUND: Ascending thoracic aortic dilation is a complex heritable trait that involves modifiable and nonmodifiable risk factors. Polygenic scores (PGS) are increasingly used to assess risk for complex diseases. The degree to which a PGS can improve aortic diameter prediction in diverse populations is unknown. Presently, we tested whether adding a PGS to clinical prediction algorithms improves performance in a diverse biobank. METHODS: The analytic cohort comprised 6235 Penn Medicine Biobank participants with available echocardiography and clinical data linked to genome-wide genotype data. Linear regression models were used to integrate PGS weights derived from a genome-wide association study of thoracic aortic diameter performed in the UK Biobank and were compared with the performance of the previously published aorta optimized regression for thoracic aneurysm (AORTA) score. RESULTS: Cohort participants had a median age of 61 years (IQR, 53–70) and a mean ascending aortic diameter of 3.36 cm (SD, 0.49). Fifty-five percent were male, and 33% were genetically similar to an African reference population. Compared with the AORTA score, which explained 30.6% (95% CI, 29.9%–31.4%) of the variance in aortic diameter, AORTA score+UK Biobank–derived PGS explained 33.1%, (95% CI, 32.3%–33.8%), the reweighted AORTA score explained 32.5% (95% CI, 31.8%–33.2%), and the reweighted AORTA score+UK Biobank–derived PGS explained 34.9% (95% CI, 34.2%–35.6%). When stratified by population, models including the UK Biobank–derived PGS consistently improved upon the clinical AORTA score among individuals genetically similar to a European reference population but conferred minimal improvement among individuals genetically similar to an African reference population. Comparable performance disparities were observed in models developed to discriminate cases/noncases of thoracic aortic dilation (≥4.0 cm). CONCLUSIONS: We demonstrated that inclusion of a UK Biobank–derived PGS to the AORTA score confers a clinically meaningful improvement in model performance only among individuals genetically similar to European reference populations and may exacerbate existing health care disparities.